Prakash Rucktooa

Prakash Rucktooa

Auto-generated profile, based on publicly available information

Prakash Rucktooa

Division of Biochemistry and Center for Biomedical Genetics, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2007 in Science
Verified
Journal Article
Closed access
PDF file
BCBernard Clantin
Bernard Clantin
ADAnne-Sophie Delattre
Anne-Sophie Delattre
PRPrakash Rucktooa
Prakash Rucktooa
NSNathalie Saint
Nathalie Saint
AMAlbano Meli
Albano Meli
VVVincent Villeret
Vincent Villeret
In Gram-negative bacteria and eukaryotic organelles, β-barrel proteins of the outer membrane protein 85–two-partner secretion B (Omp85-TpsB) superfamily are essential components of protein transport machineries. The TpsB transporter FhaC mediates the secretion of Bordetella pertussis filamentous hemagglutinin (FHA). We report the 3.15 Å crystal structure of FhaC. The transporter comprises a 16-stranded β barrel that is occluded by an N-terminal α helix and an extracellular loop and a periplasmic module composed of two aligned polypeptide-transport–associated (POTRA) domains. Functional data reveal that FHA binds to the POTRA 1 domain via its N-terminal domain and likely translocates the adhesin-repeated motifs in an extended hairpin conformation, with folding occurring at the cell surface. General features of the mechanism obtained here are likely to apply throughout the superfamily.

1 October 2009 in Biochemical Pharmacology
Verified
Journal Article
Closed access
PRPrakash Rucktooa
Prakash Rucktooa
ASAugust B. Smit
August B. Smit
TSTitia K. Sixma
Titia K. Sixma

1 November 2021 in Cell
Verified
Journal Article
Open access
ABAlastair J.H. Brown
Alastair J.H. Brown
SBSophie J. Bradley
Sophie J. Bradley
FMFiona H. Marshall
Fiona H. Marshall
GBGiles A. Brown
Giles A. Brown
KBKirstie A. Bennett
Kirstie A. Bennett
ATAndrew B. Tobin
Andrew B. Tobin
Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. An alternative approach is to directly activate cholinergic receptors responsible for learning and memory. The M1-muscarinic acetylcholine (M1) receptor is the target of choice but has been hampered by adverse effects. Here we aimed to design the drug properties needed for a well-tolerated M1-agonist with the potential to alleviate cognitive loss by taking a stepwise translational approach from atomic structure, cell/tissue-based assays, evaluation in preclinical species, clinical safety testing, and finally establishing activity in memory centers in humans. Through this approach, we rationally designed the optimal properties, including selectivity and partial agonism, into HTL9936-a potential candidate for the treatment of memory loss in Alzheimer's disease. More broadly, this demonstrates a strategy for targeting difficult GPCR targets from structure to clinic.

3 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
JSJendrik Schöppe
Jendrik Schöppe
JEJanosch Ehrenmann
Janosch Ehrenmann
CKChristoph Klenk
Christoph Klenk
PRPrakash Rucktooa
Prakash Rucktooa
MSMarco Schütz
Marco Schütz
APAndreas Plückthun
Andreas Plückthun
Neurokinins (or tachykinins) are peptides that modulate a wide variety of human physiology through the neurokinin G protein-coupled receptor family, implicated in a diverse array of pathological processes. Here we report high-resolution crystal structures of the human NK1receptor (NK1R) bound to two small-molecule antagonist therapeutics – aprepitant and netupitant and the progenitor antagonist CP-99,994. The structures reveal the detailed interactions between clinically approved antagonists and NK1R, which induce a distinct receptor conformation resulting in an interhelical hydrogen-bond network that cross-links the extracellular ends of helices V and VI. Furthermore, the high-resolution details of NK1R bound to netupitant establish a structural rationale for the lack of basal activity in NK1R. Taken together, these co-structures provide a comprehensive structural basis of NK1R antagonism and will facilitate the design of new therapeutics targeting the neurokinin receptor family.

8 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PRPrakash Rucktooa
Prakash Rucktooa
RCRobert K. Y. Cheng
Robert K. Y. Cheng
ESElena Segala
Elena Segala
TGTian Geng
Tian Geng
JEJames C. Errey
James C. Errey
ADAndrew S. Doré
Andrew S. Doré
Here we report an efficient method to generate multiple co-structures of the A2A G protein-coupled receptor (GPCR) with small-molecules from a single preparation of a thermostabilised receptor crystallised in Lipidic Cubic Phase (LCP). Receptor crystallisation is achieved following purification using a low affinity “carrier” ligand (theophylline) and crystals are then soaked in solutions containing the desired (higher affinity) compounds. Complete datasets to high resolution can then be collected from single crystals and seven structures are reported here of which three are novel. The method significantly improves structural throughput for ligand screening using stabilised GPCRs, thereby actively driving Structure-Based Drug Discovery (SBDD).

18 February 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JCJohn A. Christopher
John A. Christopher
ZOZoltán Orgován
Zoltán Orgován
MCMiles Congreve
Miles Congreve
ADAndrew S. Doré
Andrew S. Doré
JEJames C. Errey
James C. Errey
György M KeserűGyörgy M Keserű
György M Keserű